lovastatin has been researched along with Lymphoma, Primary Effusion in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cirone, M; D'Orazi, G; Gilardini Montani, MS; Gonnella, R; Pompili, C; Romeo, MA; Santarelli, R | 1 |
1 other study(ies) available for lovastatin and Lymphoma, Primary Effusion
| Article | Year |
|---|---|
Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Humans; Lovastatin; Lymphoma, Primary Effusion; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; STAT3 Transcription Factor; Tumor Suppressor Protein p53; Tyrosine | 2021 |